Key result
Early SGLT2 inhibitors reduce HF hospitalizations, CKD progression, and major CV events in T2D.
Why the study?
Type 2 diabetes is often diagnosed late when microvascular or macrovascular complications are already present, and early hyperglycemic exposure contributes to long-term cardiovascular consequences. This review analyzes the rationale and evidence supporting the early use of SGLT2 inhibitors as an organ-protective strategy in type 2 diabetes.
Does early treatment with SGLT2 inhibitors reduce heart failure hospitalizations, chronic kidney disease progression, and major cardiovascular events in patients with type 2 diabetes?
Does early treatment with SGLT2 inhibitors reduce heart failure hospitalizations, chronic kidney disease progression, and major cardiovascular events in patients with type 2 diabetes?
This review summarizes the evidence and guideline convergence supporting the early, HbA1c-independent use of SGLT2 inhibitors in type 2 diabetes for cardiorenal organ protection, including in patients without overt cardiorenal disease.
Answers are grounded in this paper and cite their sources.
Supports risk-based early SGLT2 inhibitor initiation in type 2 diabetes; extends evidence synthesis on HbA1c-independent cardiorenal benefits.
Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have fundamentally transformed the treatment of type 2 diabetes, shifting the focus from an exclusively glucocentric, treat-to-target strategy to an organ-protective, treat-to-benefit strategy.This review analyzes the rationale and evidence supporting the early use of SGLT2 inhibitors in type 2 diabetes.Diabetes is often diagnosed late, and a significant proportion of patients already have microvascular or macrovascular complications by the time the disease is clinically identified.Furthermore, early hyperglycemic exposure contributes to the so-called legacy effect, with long-term cardiovascular consequences.SGLT2 inhibitors have demonstrated consistent benefits in reducing hospitalizations for heart failure, progression of chronic kidney disease, and, in specific populations, major cardiovascular events.In recent years, guidelines have recommended early use of SGLT2 inhibitors, as substantial evidence shows their benefits in patients without overt cardiorenal disease.International and national guidelines are converging on SGLT2 inhibitors based on cardiorenal risk, often independent of glycated haemoglobin (HbA1c). KEY WORDS type 2 diabetes;
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in Type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) was evaluated on Hospitalizations for heart failure, progression of chronic kidney disease, and major cardiovascular events. SGLT2 inhibitors used early in type 2 diabetes reduce heart failure hospitalizations, chronic kidney disease progression, and major cardiovascular events independent of HbA1c.
Synapse has enriched 10 related papers. Consider them for comparative context: